72399-18-9

Upstream product

• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 50-00-0 formaldehyd 
• 622-33-3 N-benzyloxyamine 

Downstream Products

• 4404-61-9 cyclohexyldiphenylmethanol 
• 4383-24-8 N,O-dibenzylhydroxylamine 
• 64357-69-3 (4-cyclohexylphenyl)(phenyl)methanone 
• 71663-75-7 N-(benzyloxy)-3,3-dimethyl-2-azetidinone 
• 101518-64-3 1,3-Bis-benzyloxy-5-isopropyl-tetrahydro-pyrimidin-4-one 
• 112712-24-0 O-benzyl-N-neopentylhydroxylamine 
• 6284-07-7 N-n-butyl-N-n-pentylbenzylamine 
• 791590-47-1 1-(benzyloxy)-3-pentylazetidin-2-one 
• 457897-19-7 (R)-1-(benzyloxy)-3-pentylazetidin-2-one 
• 457897-20-0 (R)-2-(((benzyloxy)amino)methyl)heptanoic acid 
• 457897-21-1 (2R)-2-({formyl[(phenylmethyl)oxy]amino}methyl)heptanoic acid 

Relevant academic research and scientific papers

Concise synthesis of 2-N-hydroxy-3,4-dihydroisoquinol-2-one: A bacterial siderophore and human 5-lipooxygenase inhibitor

A short synthesis of 2-N-hydroxy-3,4-dihydroisoquinol-2-one has been devised, which is based on the Castagnoli-Cushman reaction and 3 times more high-yielding compared to an earlier reported sequence.

2-Unsubstituted Imidazole N-Oxides as Novel Precursors of Chiral 3-Alkoxyimidazol-2-ylidenes Derived from trans-1,2-Diaminocyclohexane and Other Chiral Amino Compounds

‘Desymmetrization’ of trans-1,2-diaminocyclohexane by treatment with α,ω-dihalogenated alkylation reagents leads to mono-NH2 derivatives (‘primary-tertiary diamines’). Upon reaction with formaldehyde, these products formed monomeric formaldimines. Subsequently, reactions of the formaldimines with α-hydroxyiminoketones led to the corresponding 2-unsubstituted imidazole N-oxide derivatives, which were used here as new substrates for the in situ generation of chiral imidazol-2-ylidenes. Upon O-selective benzylation, new chiral imidazolium salts were obtained, which were deprotonated by treatment with triethylamine in the presence of elemental sulfur. Under these conditions, the intermediate imidazol-2-ylidenes were trapped by elemental sulfur, yielding the corresponding chiral non-enolizable imidazole-2-thiones in good yields. Analogous reaction sequences, starting with imidazole N-oxides derived from enantiopure primary amines, amino alcohols, and amino acids, leading to the corresponding 3-alkoxyimidazole-2-thiones were also studied.

SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

PROCESS FOR PREPARING PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to processes for making {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl) hydrazino]-3-oxopropyl}hydroxyformamide compounds of Formula (I), or pharmaceutically acceptable salts thereof and corresponding intermediates thereof, where su

Alkoxyamino glycoside acceptors for the regioselective synthesis of oligosaccharides using glycosynthases and transglycosidases

Alkoxyamino derivatives of oligosaccharides have been synthesized by enzymatic synthesis using a glycosynthase and a transglycosidase. The chemoselective assembly of unprotected oligosaccharides bearing glucose at the reducing end with N-alkyl-O-benzylhydroxylamine provides sugar derivatives that are good acceptors for enzymatic synthesis using either glycosynthase or transglycosidase. Furthermore, this method affords the possibility of controlling the regioselectivity of coupling depending on the nature of the alkoxyamino substituent and provides high-yield coupling of sugars without the need for complex protecting group chemistry.

Conformational analysis of a secondary hydroxamic acid in aqueous solution by NOE spectroscopy

Hydroxamic acids are metal-binding compounds used by micro-organisms and possess applications in medicine and industry. Hydroxamic acids favor two conformations, E and Z; metal binding is limited to the Z conformation. The Z conformation may be identifiab